Name | Number of supported studies | Average coverage | |
---|---|---|---|
B cell | 22 studies | 28% ± 8% | |
plasma cell | 18 studies | 43% ± 15% | |
naive B cell | 17 studies | 27% ± 8% | |
plasmablast | 11 studies | 45% ± 23% | |
memory B cell | 9 studies | 26% ± 6% | |
non-classical monocyte | 7 studies | 26% ± 9% | |
astrocyte | 6 studies | 33% ± 10% | |
macrophage | 6 studies | 26% ± 10% | |
IgA plasma cell | 5 studies | 35% ± 14% | |
IgG plasma cell | 5 studies | 28% ± 13% | |
plasmacytoid dendritic cell | 5 studies | 22% ± 6% | |
hematopoietic precursor cell | 4 studies | 28% ± 8% | |
epithelial cell of proximal tubule | 4 studies | 22% ± 4% | |
immature B cell | 4 studies | 29% ± 9% | |
dendritic cell | 4 studies | 23% ± 7% | |
germinal center B cell | 4 studies | 34% ± 12% | |
conventional dendritic cell | 3 studies | 39% ± 21% | |
GABAergic neuron | 3 studies | 27% ± 4% | |
glutamatergic neuron | 3 studies | 34% ± 2% | |
granulocyte monocyte progenitor cell | 3 studies | 28% ± 12% | |
hematopoietic stem cell | 3 studies | 20% ± 6% | |
microglial cell | 3 studies | 21% ± 5% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 3 studies | 28% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 459.74 | 245 / 245 | 100% | 25.40 | 500 / 502 |
brain | 100% | 167.93 | 2638 / 2642 | 99% | 8.29 | 701 / 705 |
lung | 99% | 150.36 | 572 / 578 | 99% | 8.68 | 1143 / 1155 |
breast | 100% | 125.40 | 459 / 459 | 97% | 9.08 | 1081 / 1118 |
bladder | 100% | 129.33 | 21 / 21 | 94% | 6.84 | 476 / 504 |
intestine | 99% | 170.14 | 959 / 966 | 94% | 5.37 | 496 / 527 |
pancreas | 98% | 112.87 | 320 / 328 | 94% | 5.76 | 167 / 178 |
stomach | 96% | 90.18 | 345 / 359 | 95% | 6.35 | 271 / 286 |
kidney | 100% | 505.31 | 89 / 89 | 90% | 6.96 | 811 / 901 |
uterus | 93% | 63.75 | 158 / 170 | 97% | 10.89 | 443 / 459 |
esophagus | 94% | 73.17 | 1363 / 1445 | 93% | 5.45 | 170 / 183 |
thymus | 94% | 84.44 | 617 / 653 | 81% | 4.76 | 489 / 605 |
ovary | 82% | 56.73 | 147 / 180 | 87% | 3.82 | 372 / 430 |
adrenal gland | 98% | 103.34 | 252 / 258 | 60% | 2.19 | 138 / 230 |
skin | 69% | 36.98 | 1241 / 1809 | 66% | 4.48 | 311 / 472 |
liver | 73% | 55.20 | 166 / 226 | 58% | 2.40 | 237 / 406 |
lymph node | 0% | 0 | 0 / 0 | 100% | 71.94 | 29 / 29 |
spleen | 100% | 765.29 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 14.94 | 45 / 45 |
adipose | 99% | 111.12 | 1194 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 103.36 | 1318 / 1335 | 0% | 0 | 0 / 0 |
muscle | 95% | 74.21 | 765 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 92% | 513.34 | 858 / 929 | 0% | 0 | 0 / 0 |
heart | 89% | 79.15 | 764 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 9% | 0.40 | 7 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006915 | Biological process | apoptotic process |
GO_0060770 | Biological process | negative regulation of epithelial cell proliferation involved in prostate gland development |
GO_0006368 | Biological process | transcription elongation by RNA polymerase II |
GO_0034243 | Biological process | regulation of transcription elongation by RNA polymerase II |
GO_0060767 | Biological process | epithelial cell proliferation involved in prostate gland development |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0030308 | Biological process | negative regulation of cell growth |
GO_0032783 | Cellular component | super elongation complex |
GO_0016607 | Cellular component | nuclear speck |
GO_0005654 | Cellular component | nucleoplasm |
GO_0008023 | Cellular component | transcription elongation factor complex |
GO_0005515 | Molecular function | protein binding |
GO_0003711 | Molecular function | transcription elongation factor activity |
Gene name | EAF2 |
Protein name | ELL-associated factor 2 (Testosterone-regulated apoptosis inducer and tumor suppressor protein) ELL associated factor 2 ELL associated factor 2 (cDNA FLJ60185, highly similar to ELL-associated factor 2) |
Synonyms | TRAITS BM-040 |
Description | FUNCTION: Acts as a transcriptional transactivator of TCEA1 elongation activity (By similarity). Acts as a transcriptional transactivator of ELL and ELL2 elongation activities. Potent inducer of apoptosis in prostatic and non-prostatic cell lines. Inhibits prostate tumor growth in vivo. . |
Accessions | F8WF04 ENST00000490434.5 F8WCI9 ENST00000273668.7 [Q96CJ1-1] Q96CJ1 ENST00000490477.1 ENST00000451944.2 B4DWJ3 |